Clinical Impact Costs and Costeffectiveness of Expanded Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Massachusetts

Anne M NeilanElena LosinaAudrey C BangsClare FlanaganA Et AlGuy Harling2023-04-172023-04-17WOS1058-4838https://hdl.handle.net/10539/35237Clinical Impact Costs and Costeffectiveness of Expanded Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Massachusetts